[go: up one dir, main page]

AR014167A1 - UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE. - Google Patents

UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE.

Info

Publication number
AR014167A1
AR014167A1 ARP980106652A ARP980106652A AR014167A1 AR 014167 A1 AR014167 A1 AR 014167A1 AR P980106652 A ARP980106652 A AR P980106652A AR P980106652 A ARP980106652 A AR P980106652A AR 014167 A1 AR014167 A1 AR 014167A1
Authority
AR
Argentina
Prior art keywords
amid
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition containing
Prior art date
Application number
ARP980106652A
Other languages
English (en)
Inventor
Louis Junien Jean
J M Riviere Pierre
D Schteingart Claudio
Sueiras Diaz Javier
A Trojnar Jerzy
W Vanderah Todd
Original Assignee
Cara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cara Therapeutics Inc filed Critical Cara Therapeutics Inc
Publication of AR014167A1 publication Critical patent/AR014167A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1027Tetrapeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dichos péptidos exhiben alta selectividad por el receptor opioide Kappa (KOR) y larga duracion de accion periférica sin entrada significativa en elcerebro, éstos son secuencias de 4 residuos de aminoácidos de D-isomero que tienen un C-termina l que es una amida mono o di-sustituida. Tiene afinidad porel receptor opioide Kappa la cual es por lo menos 1000 veces la afinidad para el receptor opioide mu y exhibe larga duracion de accion cuando se administrain vivo.
ARP980106652A 1997-12-23 1998-12-23 UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE. AR014167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/997,208 US5965701A (en) 1997-12-23 1997-12-23 Kappa receptor opioid peptides

Publications (1)

Publication Number Publication Date
AR014167A1 true AR014167A1 (es) 2001-02-07

Family

ID=25543752

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106652A AR014167A1 (es) 1997-12-23 1998-12-23 UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE.

Country Status (32)

Country Link
US (1) US5965701A (es)
EP (1) EP1042359B1 (es)
JP (1) JP4275852B2 (es)
KR (1) KR100629548B1 (es)
CN (1) CN1154655C (es)
AR (1) AR014167A1 (es)
AT (1) ATE301670T1 (es)
AU (1) AU747806B2 (es)
BR (2) BR9814499B1 (es)
CA (1) CA2315878C (es)
CR (1) CR5936A (es)
CZ (1) CZ297281B6 (es)
DE (1) DE69831176T2 (es)
DK (1) DK1042359T3 (es)
EE (1) EE04440B1 (es)
ES (1) ES2247735T3 (es)
HR (1) HRP20000415B1 (es)
HU (1) HU227640B1 (es)
IL (3) IL136742A0 (es)
MY (1) MY117542A (es)
NO (1) NO327080B1 (es)
NZ (1) NZ505183A (es)
PL (1) PL195842B1 (es)
PT (1) PT1042359E (es)
RU (1) RU2217437C2 (es)
SK (1) SK286135B6 (es)
TR (1) TR200001985T2 (es)
TW (1) TW580502B (es)
UA (1) UA68366C2 (es)
UY (1) UY25327A1 (es)
WO (1) WO1999032510A1 (es)
ZA (1) ZA9811801B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
EP1402899A4 (en) * 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
PT1494732E (pt) 2002-03-20 2008-03-20 Mannkind Corp Aparelho de inalação
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
CN101454017A (zh) * 2006-05-26 2009-06-10 卡拉治疗学股份有限公司 提升哺乳动物催乳素的方法
US20100029575A1 (en) * 2006-05-26 2010-02-04 Jean-Louis Junien N-Oxides of Kappa Receptor Peptides
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
JP5244810B2 (ja) * 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
WO2008077194A1 (en) * 2006-12-22 2008-07-03 Xenome Ltd Receptor agonists
RU2608439C2 (ru) 2008-06-13 2017-01-18 Маннкайнд Корпорейшн Ингалятор для сухого порошка и система для доставки лекарственных средств
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) * 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
KR102303092B1 (ko) * 2014-06-26 2021-09-15 마루이시세이야쿠가부시키가이샤 합성 펜타펩티드의 제조법
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016181408A2 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
EP3521301B1 (en) * 2016-09-27 2024-03-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Polyamide compound and use thereof
PT3656782T (pt) 2017-07-21 2022-02-08 Sichuan Haisco Pharmaceutical Co Ltd Composto amida peptídica e o seu método de preparação e utilização médica
MX2020005932A (es) 2017-12-06 2020-08-24 Jiangsu Hengrui Medicine Co Sal de derivado de fenilpropionamida y su metodo de preparacion.
TW202015716A (zh) 2018-05-16 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種kor受體激動劑醫藥組成物
WO2021013085A1 (zh) * 2019-07-25 2021-01-28 四川海思科制药有限公司 一种肽酰胺盐及其制备方法和在医药上的用途
WO2021013086A1 (zh) * 2019-07-25 2021-01-28 四川海思科制药有限公司 氘代肽酰胺类化合物及其制备方法和在医药上的用途
WO2021026492A1 (en) * 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
WO2021262173A1 (en) 2020-06-25 2021-12-30 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
WO2023278843A2 (en) 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2013689B (en) * 1977-12-15 1982-03-24 Reckitt & Colmann Prod Ltd Compounds
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
US5367053A (en) * 1993-05-19 1994-11-22 Houghten Pharmaceuticals, Inc. Opioid peptide inhibitors
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides

Also Published As

Publication number Publication date
BR9814499B1 (pt) 2014-10-21
CR5936A (es) 2006-08-18
SK286135B6 (sk) 2008-04-07
ZA9811801B (en) 1999-06-22
BR9814499A (pt) 2000-10-10
HRP20000415A2 (en) 2000-12-31
DE69831176T2 (de) 2006-04-20
TR200001985T2 (tr) 2000-11-21
JP4275852B2 (ja) 2009-06-10
CN1154655C (zh) 2004-06-23
MY117542A (en) 2004-07-31
EP1042359A1 (en) 2000-10-11
BRPI9814499A (pt) 2000-10-10
PT1042359E (pt) 2005-11-30
EE04440B1 (et) 2005-02-15
KR100629548B1 (ko) 2006-09-27
CZ20002382A3 (cs) 2000-12-13
HRP20000415B1 (en) 2004-06-30
BRPI9814499B8 (pt) 2021-11-09
BRPI9814499B1 (pt) 2014-10-21
ES2247735T3 (es) 2006-03-01
CZ297281B6 (cs) 2006-10-11
RU2217437C2 (ru) 2003-11-27
CN1283201A (zh) 2001-02-07
WO1999032510A1 (en) 1999-07-01
UA68366C2 (en) 2004-08-16
HU227640B1 (en) 2011-10-28
IL178471A0 (en) 2007-02-11
IL136742A (en) 2006-12-31
HUP0100626A3 (en) 2001-12-28
TW580502B (en) 2004-03-21
EE200000370A (et) 2001-10-15
JP2001526295A (ja) 2001-12-18
HK1029349A1 (en) 2001-03-30
CA2315878A1 (en) 1999-07-01
NO327080B1 (no) 2009-04-20
EP1042359B1 (en) 2005-08-10
NO20003245L (no) 2000-08-23
NO20003245D0 (no) 2000-06-21
AU747806B2 (en) 2002-05-23
HUP0100626A2 (hu) 2001-08-28
UY25327A1 (es) 2000-12-29
IL136742A0 (en) 2001-06-14
CA2315878C (en) 2010-11-16
AU1940299A (en) 1999-07-12
DK1042359T3 (da) 2005-11-28
PL341308A1 (en) 2001-04-09
WO1999032510A9 (en) 1999-09-23
PL195842B1 (pl) 2007-10-31
DE69831176D1 (de) 2005-09-15
US5965701A (en) 1999-10-12
SK9602000A3 (en) 2001-01-18
KR20010033450A (ko) 2001-04-25
ATE301670T1 (de) 2005-08-15
NZ505183A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
AR014167A1 (es) UNA AMIDA PEPTíDICA OPIOIDE SINTÉTICA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y COMPOSICIoN FARMACÉUTICA QUE LA CONTIENE.
DE60037800D1 (de) Stereoselektive antifibrillogene peptide
Veber et al. The design of metabolically-stable peptide analogs
Chen et al. Structure–bioactivity of C‐terminal pentapeptide of osteogenic growth peptide [OGP (10–14)]
BG107242A (en) Modulator of the parathyroid hormone receptors and protein of parathyroid-related hormone
EA199900490A1 (ru) СПОСОБЫ И СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ ВЫДЕЛЕНИЯ β-АМИЛОИДНОГО ПЕПТИДА И/ИЛИ ЕГО СИНТЕЗА
JP2003503312A5 (es)
CA2284547A1 (en) Mu-opiate receptor peptides
HRP950413A2 (en) Novel opioid peptides for the treatment of pain and use thereof
ES8300087A1 (es) Procedimiento para preparar amidas tetrapeptidas n-adamantano-sustituidas.
ATE278708T1 (de) Conotoxin peptid pviia
CA2550085A1 (en) Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
JPH03120296A (ja) 放射性元素標識化抗凝固ペプチド
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
RU2001127246A (ru) Соединения-модуляторы пептида β-амилоида (варианты), фармацевтическая композиция, способ предотвращения агрегации природных пептидов β-амилоида, способ обнаружения присутствия или отсутствия природных пептидов β-амилоида в биологическом образце и способ лечения заболевания у субъекта, ассоциированного с β-амилоидозом
RU2223970C2 (ru) Лечение ожирения
WO2002005748A3 (en) Medicinal uses of mu-opioid receptor agonists
EA200501131A1 (ru) Парентеральные композиции пептидов для лечения системной красной волчанки
FI941860A0 (fi) Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
Kisara et al. Dermorphin analogues containing D-kyotorphin: structure-antinociceptive relationships in mice
EP0815870A2 (en) Composition for prohylaxis or treatment of cerebral infarction
WO1998031705A1 (en) Bromo-tryptophan conopeptides
AU719632B2 (en) Contryphan peptides
RU2001113277A (ru) Регуляторные/развернутые пептиды эзрина
WO2007144979A1 (ja) ペプチド誘導体

Legal Events

Date Code Title Description
FG Grant, registration